



HELP YOUR PATIENTS REDISCOVER THE COLOUR OF LIFE

A proven treatment for patients suffering from Major Depressive Disorder



**MAGSTIM RAPID²
THERAPY SYSTEM**

THE BRAINS BEHIND TMS™

ADVANTAGES OF MAGSTIM TMS THERAPY

- ✓ Fast and significant patient improvement
- ✓ Provided as outpatient procedure
- ✓ Patients can return to normal activities after treatment
- ✓ No anesthesia or sedation required
- ✓ Proven efficacy with no systemic side effects*

MAGSTIM TMS THERAPY, REDEFINING THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Magstim's Rapid² Therapy System is a non-invasive device for people suffering from treatment-resistant Major Depressive Disorder (MDD). Globally, more than 350 million people of all ages suffer from depression¹, affecting their ability to lead a normal life. By the year 2030, depression is predicted to become the number one cause of disability².



PROVEN EFFICACY WITHOUT SYSTEMIC SIDE EFFECTS

Magstim's Rapid² Therapy System is a proven, cost-effective treatment for MDD. Unlike traditional drug treatment, transcranial magnetic stimulation is a safe non-invasive therapy with no systemic side effects.

It has been shown that the majority of depression episodes (>65%) result in non-remission after first-line treatment with any chosen anti-depressant medication³.

Using TMS, it was demonstrated that refractory MDD patients showed an improvement in depression scores⁴. Indeed, a multisite, naturalistic, observational study of 307 patients showed that 58% of patients responded positively to TMS therapy and 37.1% of patients went into remission⁵.

The Magstim Rapid² Therapy System is a non-invasive treatment for people who suffer from drug-resistant Major Depressive Disorder. TMS has none of the known systematic side effects of drugs or ECT treatment.

The Magstim Rapid² Therapy System's efficacy is substantially equivalent to other systems on the market and combined with the Magstim Difference, we are redefining the treatment of drug-resistant depression.

COMPARABLE DEPRESSION TREATMENT SIDE EFFECTS

	Anti-depressants	ECT	TMS
Anxiety	●	●	
Blurred Vision	●		
Diarrhea / Constipation	●		
Dizziness	●	●	● Transient
Dry mouth	●	●	
Headache	●		● Transient
Insomnia / Drowsiness	●	●	
Nausea	●	●	
Sexual Dysfunction	●		
Weight gain	●		
Memory Loss	●	●	

"I'm relieved and thankful there's an effective, non-drug treatment that's applied directly to my brain, that doesn't affect the rest of my body. Not only have I recaptured my life, I've actually gained more than I had to begin with."

Martha Rhodes, author of "3000 Pulses Later - A Memoir of Surviving Depression Without Medication"

THE RAPID² THERAPY SYSTEM

Intuitive, compact and simple to operate, the plug-and-play Rapid² Therapy System is the TMS system to help you set-up your TMS clinic today.

Double 70mm Air Film Coil
Efficient self-regulating temperature control for uninterrupted treatment

Head Support System
Provides contralateral support to ensure coil-to-patient contact throughout treatment duration

Therapy Chair
Mobile and motorised, it is fully adjustable for patient comfort and stillness

Double 70mm Alpha Coil
A hand-held coil for Motor Threshold assessment. Coil can also be triggered via Magstim foot switch

Rapid² Therapy Stimulator
Capable of repetitive mode output at high power levels. Reliable and easy to set-up for delivering protocol

Rapid Trolley
Transportable, easy to install and secure solution with a small footprint



Patient Cap

Ideal for site location marking, it allows for repeatable coil positioning and shortens the treatment set-up time.

Northamptonshire Healthcare NHS Foundation Trust (NHFT) is leading the way in innovative mental health treatments and has integrated TMS Therapy into its ECT unit.

“Integrating TMS therapy into our ECT delivery team has allowed us to expand our treatment offering. This now improves the efficiency of our ECT team, improves the use of our ECT facilities and ultimately, provides improved patient choice.”

**Dr Alex O'Neill-Kerr / Medical Director / Consultant Psychiatrist
Northamptonshire Healthcare NHS
Foundation Trust**



MAGSTIM NHS OPEN DAYS - UNDERSTANDING THE BENEFITS OF TMS THERAPY

In partnership with NHFT, Magstim frequently run NHS Open Day workshops.

The one day course includes interactive lectures, a visit to the TMS centre, demonstrations and practical workshops on Magstim TMS equipment.

What will I gain from the course?

- ✓ A clinical understanding of how TMS works in the treatment of Major Depressive Disorder
- ✓ The ability to identify which patients will benefit from the treatment
- ✓ An overview of TMS in a clinical setting and practical insight into delivering TMS treatments
- ✓ An understanding of what is required to set up a TMS clinic

If you feel that you, or members of your institution may benefit from one of our events, please visit:

www.magstim.com/news-and-events or email us at: conferences@magstim.com

“It has given me my life back”

Sarah, former long-term depression sufferer

Sarah had suffered from drug-resistant MDD for over 13 years. She had low mood, OCD, and anorexia and was regularly self-harming. In addition to her mental condition, Sarah also had a physical disability. She describes her former self as insular. She was struggling to hold a conversation and lacked the motivation to cope with daily tasks. Sarah had a constant feeling of “complete numbness.”

Several days into her TMS treatment for depression, Sarah described how she suddenly managed to finish household chores and rediscovered the pleasure of laughing with her partner over little things. She repeatedly expressed “feelings of sheer joy” when seeing her partner and daughter waiting for her at the hospital.



“Following the treatment, everything seemed lighter. When I finished my treatment session, I felt like the flowers in my garden; I had been dormant for such a long time and all of a sudden, everything was opening up with colour.”

Sarah has decided to share her TMS experience with other depression sufferers and developed a patient support group at her local trust: “It has given me my life back,” she says.



WHAT ARE NICE SAYING ABOUT TMS?

The National Institute for Health and Care Excellence (NICE) updated its guidance on TMS for the treatment of depression in December 2015.

The guidance states that “there are no major safety concerns and that its (TMS) efficacy in the short term is adequate. TMS stimulation for depression may also be used with normal arrangements for clinical governance and audit.”

Source: www.nice.org.uk/guidance/ipg542

THE MAGSTIM DIFFERENCE

Magstim has used the power of neurostimulation to create a simple, non-invasive and proven therapy that helps patients living with drug resistant MDD to improve their quality of life. Utilising over 30 years of insight, our personal and supportive approach is designed to enable healthcare providers to concentrate on what matters most – better patient outcomes.

- ✓ **Cost effective TMS solution** with no consumables
- ✓ **Fast Technical Support** when you need it
- ✓ **Flexible financing options** to suit your needs
- ✓ **Free 2 year warranty** with an option to extend to 5 years
- ✓ **Tailored training** 30 years of insight from the inventors of TMS

START YOUR TMS CLINIC TODAY

To find out more about our Rapid² Therapy System or request a quote, please contact us:

www.magstim.com | sales@magstim.com

Tel: +44 (0) 1994 240798

The Magstim Company Ltd
Spring Gardens,
Whitland,
Carmarthenshire,
SA34 0HR



1. Depression Fact Sheet. World Health Organisation. (2012)
2. Global Burden of Disease Report. Geneva, World Health Organisation. (2006)
3. Rush A J et al, Acute and longer-term outcomes in Depressed outpatients requiring one or several treatment steps: A STAR*D Report. Am J Psychiatry. 2006. 163, 1905-1917
4. Magstim Rapid² Therapy System 510(k) submission no. K143531
5. "Carpenter, L et al. Transcranial Magnetic Stimulation (TMS) for Major Depression: A multisite, naturalistic, observational study of acute treatment outcomes in clinical practice (2012)" *Depress Anxiety* 2012; 29, 587-596.

* There has been an infrequent report of seizures associated with TMS. The estimated seizure risk is 0.003% of treatments, or 0.1% of patients

magstim
CLINICAL